[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-mellitus-t2dm-cost-effectiveness-sulfonylureas-dpp4-inhibitors-metformin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-mellitus-t2dm-cost-effectiveness-sulfonylureas-dpp4-inhibitors-metformin":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":24,"lastUpdatePostDateStruct":25,"startDateStruct":28,"completionDateStruct":30,"leadSponsor":32,"locationsCount":5},"100559964",false,"NCT06570980","Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","Inclusion Criteria:\n\n* New onset type2 diabetes mellitus diagnosed for 2 -5 years.\n* Taking either sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.\n* Age 18 years or above.\n* Both male and female.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Unwillingness to participate or unwillingness to give written informed consent.\n* Patients on Insulin therapy or monotherapy with metformin since the time of diagnosis.\n* Taking other than sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.\n* Diabetes related complications at the time of diagnosis.","ALL","18 Years",{"count":17,"type":18},200,"ESTIMATED","OBSERVATIONAL","The aim of this study is to compare the cost effectiveness of Sulfonylureas and DPP4-inhibitors in combination with Metformin among type2 diabetic patients diagnosed for 2-5 years. Glycemic status and other clinical outcome are compared in between two groups and ICER are compared.",[22],"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","RECRUITING","2024-08-22",{"date":26,"type":27},"2024-08-26","ACTUAL",{"date":29,"type":27},"2023-08-25",{"date":31,"type":18},"2024-08-30",{"name":33,"class":34},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","OTHER",""]